Scoring criteria for the evaluation of micronuclei in oral exfoliated cells DOI: 10.4103/2278-330X.208842 Dear Editor, With reference to the article titled, "An in vivo cytogenetic analysis of human oral squamous cell carcinoma" [1] published in your esteemed journal, I would like to bring into notice a few important points regarding the scoring criteria used for the evaluation of micronuclei.
The criteria used for the evaluation of micronuclei in the above-mentioned study are as follows: [2] • The diameter of micronucleus (MN) in human lymphocytes usually varies between 1/16 and 1/3 of the mean diameter of the main nuclei which corresponds to 1/256 and 1/9 of the area of one of the main nuclei in a BN cell, respectively • MN is round or oval • MN is nonrefractile and it can, therefore, be readily distinguished from artifacts such as staining particles • MN is not linked or connected to the main nuclei • MN may touch but will not overlap the main nuclei, and the micronuclear boundary should be distinguishable from the nuclear boundary • MN usually has the same staining intensity as the main nuclei but occasionally staining may be more intense.
First of all, the above-said criteria are for the evaluation of micronuclei in lymphocytes and not exfoliated oral cells (as in the given study, micronuclei were evaluated in exfoliated oral cells). Second, the micronuclei showed in the images provided do not comply by the criteria used (micronuclei shown in the image are refractile and overlapping). The most accepted criterion [3] for the evaluation of micronuclei in oral exfoliated cells is as follows: a. Rounded smooth perimeter suggestive of a membrane b. Less than one-third of the diameter of the associated nucleus, but large enough to discern the shape and color c. Staining intensity similar to that of the nucleus d. Texture similar to that of the nucleus e. Same focal plane as the nucleus f. Absence of overlap with, or bridge to, the nucleus. Dear Editor, A 2-year-old girl was diagnosed with stage IV neuroblastoma with initial disease sites being right adrenal mass and bone marrow (BM) with nonamplified MYCN. She received treatment as per high risk-neuroblastoma-1 (HR-NBL-1)/ESIOP protocol [1] and remained disease free for 22 months when she relapsed in the BM and lung. She received cyclophosphamide-topotecan alternate with ifosfamide-carboplatin-etoposide based salvage chemotherapy with no response after six cycles. Immunohistochemical (IHC) for anaplastic lymphoma kinase (ALK) protein using D5F3 antibody in the biopsy specimen showed strong and uniform expression of ALK. Crizotinib capsule 200 mg twice a day (265 mg/m 2 /dose) was started after informed consent as palliation, with monitoring of blood counts, liver, and kidney function. She tolerated the drug well apart from mild nausea. She improved symptomatically and evaluation after 16 weeks revealed complete response in BM and lung. Parents declined the option of hematopoietic stem cell transplant; hence, crizotinib monotherapy was continued. She remained disease-free for a total 32 weeks when she presented with fever and body ache and was confirmed to have a relapse in BM.
The second case is a 2-year-old girl who was diagnosed as a case of high-risk neuroblastoma involving right suprarenal, BM and multiple bony sites. She was treated as per HR-NBL-1/ESIOP protocol. BM disease persisted at the end of chemotherapy. Cyclophosphamide-topotecan based chemotherapy was administered as salvage with no change in disease status after two cycles. Hence, ALK protein was tested by IHC and strong expression of ALK led to the addition of crizotinib 125 mg twice
